Table 2.
Eicosanoids with significant change between normal controls and persistent AF patients
| Eicosanoids (ng/mL, range[median]) | SR group (n = 8) |
PAF group (n = 8) |
log2 (Fold change) |
-log10 (P value)a |
|---|---|---|---|---|
| 6k-PGF1α | 9.59–26.92 (16.35) | 0-2.95 (0.80) | 4.34 | 3.03 |
| PGJ2 | 0.02–0.05 (0.04) | 0.07–0.17 (0.13) | -1.82 | 3.81 |
| LTB4 | 0.05–0.13 (0.11) | 0.41–1.32 (0.95) | -3.11 | 3.81 |
| 8-HETE | 0.09–0.18 (0.13) | 0.21–2.75 (1.07) | -3.06 | 3.81 |
| 11-HETE | 0.10–0.25 (0.18) | 0.35–5.51 (1.62) | -3.21 | 3.81 |
| 5-HETE | 0.14–0.33 (0.25) | 0.37–3.93 (1.43) | -2.54 | 3.81 |
| 15-HETE | 0.44-1 (0.68) | 1.21–7.25 (2.49) | -1.88 | 3.81 |
| 12-HETE | 0.24–0.79 (0.53) | 0.71–13.47 (3.42) | -2.69 | 3.21 |
| 15-oxo-ETE | 0-0.54 (0.11) | 0.1–1.77 (0.71) | -2.73 | 2.33 |
SR: sinus rhythm; PAF: persistent atrial fibrillation
aSignificant change in level indicated fold change > 2 or < 50%, P value versus SR group